30 Day Trial
ORTHOKNOW logo

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Year in Review

2014 Revenue: K2M

4Q14 revenue: $49.3MM, +16% (U.S. $35.7MM, +25%; ex-U.S. $13.6MM, -3%)

  • U.S. Complex Spine $13.6MM, +21%
  • U.S. Minimally Invasive $5.5MM, +24%
  • U.S. Degenerative $16.5MM, +28%

 

U.S. revenue supported primarily by increase in new surgeon users, sales to existing customers and change in product mix, offset partially by price

Received CE Mark approval and FDA 510(k) clearance to market CAPRI Corpectomy Cage

 

2014 revenue: $186.7MM, +18% (U.S. $133.1MM, +19%; ex-U.S. $53.6MM, +16%)

  • U.S. Complex Spine $54.0MM, +16%
  • U.S. Minimally Invasive $20.6MM, +12%
  • U.S. Degenerative $58.4MM, +25%

 

Ended year with 12 510(k) clearances, as well as Japan regulatory clearance of SERENGETI MIS system

At year-end, claimed meaningful presence in 20 of 31 U.S. NFL cities

Added 10 new direct reps and ~20 independent sales agencies

In 1Q15, received FDA 510(k) clearance for MESA 2 Deformity system

~$35MM capital raise in 1Q will support acquisition, investment in or otherwise partnering for complementary products, technologies, businesses